線維筋痛症治療薬の世界市場2015-2019

◆英語タイトル:Global Fibromyalgia Drugs Market 2015-2019
◆発行会社/調査会社:Technavio
◆商品コード:IRTNTR6480
◆発行日:2015年7月15日
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:73
◆レポート言語:英語
◆レポート形式:pdf
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[線維筋痛症治療薬の世界市場2015-2019]についてメールでお問い合わせはこちら
当調査レポートでは、線維筋痛症治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、線維筋痛症治療薬の世界市場規模及び予測、種類別分析、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
*** レポート概要(サマリー)***

About Fibromyalgia
According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, fibromyalgia is a syndrome with an unknown cause and chronic pain and muscle tenderness as the major symptoms. Unlike arthritis, it does not cause joint, muscle or other tissue inflammation. However, fibromyalgia is known to cause impairment of joints, soft tissues, and causes significant pain and fatigue. Fibromyalgia affects women more than men. In the US, the condition affects more than 5 million people aged 18 years and above, of which 80-90% are women. There is no particular diagnostic test for detecting fibromyalgia, and physicians undertake differential diagnosis to check the presence of the syndrome. Currently in the US, only three drugs are approved to treat fibromyalgia. Off-label treatment is a popular option to treat fibromyalgia using analgesics, antidepressants, sedatives, neuroleptics, and muscle relaxants.

Technavio’s analysts forecast the global fibromyalgia drugs market to grow at a CAGR of 0.79% over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the global fibromyalgia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of fibromyalgia.

Based on the chemical class of the drugs used to treat fibromyalgia, the market is segmented as follows:
• Serotonin norepinephrine reuptake inhibitors
• GABA analogs
• Others

Technavio’s report, the Global Fibromyalgia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.

This report includes a discussion of the market in the following three regions:
• Americas: The major countries here are the US, Canada, Mexico, and Brazil
• EMEA: The major countries here are the UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
• APAC: The major countries here are Japan, China, Australia, Singapore, South Korea, and India.

APAC is a major untapped market with many leading vendors in the global fibromyalgia drugs market
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Actavis
• Eli Lilly
• Pfizer

[Other Prominent Vendors]
• Daiichi Sankyo
• Innovative Med Concepts
• Meda
• Meiji Seika
• Merck Sharp and Dohme
• Switch Biotech
• Theravance
• Tonix
• Zynerba Pharmaceuticals

[Market Driver]
• Unmet Medical Needs
• For a full, detailed list, view our report

[Market Challenge]
• Adverse Events
• For a full, detailed list, view our report

[Market Trend]
• Expected Entry of “”Me-too”” Drugs
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** レポート目次(コンテンツ)***

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1.1 Savella
04.1.2 Cymbalta
04.1.3 Lyrica

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Introduction

07.Disease Overview
07.1 Understanding the Disease
07.2 Signs and Symptoms
07.2.1 Pain and Muscle Stiffness
07.2.2 Sleep Disturbances
07.2.3 Fatigue
07.2.4 Chronic Headache
07.2.5 Other Symptoms
07.3 Epidemiology
07.4 Pathophysiology
07.5 Economic Burden
07.6 Novel Therapeutic Approach

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Fibromyalgia Drugs Market in US
08.3.1 Market Overview
08.3.2 Market Size and Forecast
08.4 Fibromyalgia Drugs Market in Europe
08.4.1 Market Overview
08.4.2 Market Size and Forecast
08.5 Five Forces Analysis

09.Market Segmentation by Chemical Class of Drug
09.1 Global Fibromyalgia Drugs Market by Chemical Class of Drug 2014-2019
09.2 Serotonin-norepinephrine Reuptake Inhibitors
09.3 GABA Analogs
09.4 Others

10.Geographical Segmentation
10.1 Global Fibromyalgia Drugs Market by Geography 2014-2019

11.Buying Criteria

12.Pipeline Portfolio
12.1 Key Information on Pipeline Candidates
12.1.1 TNX-102 SL
12.1.2 Lyrica CR
12.1.3 DS-5655
12.1.4 TD-9855
12.1.5 IMC-1
12.1.6 Mirtazapine
12.1.7 Flupirtine
12.1.8 SWT06101
12.1.9 ZYN001

13.Market Growth Drivers

14.Drivers and Their Impact

15.Market Challenges

16.Impact of Drivers and Challenges

17.Market Trends

18.Trends and Their Impact

19.Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Major Vendor Analysis 2014
19.2.1 Pfizer
19.2.2 Eli Lilly
19.2.3 Actavis
19.3 Other and Future Prominent Vendors

20.Key Vendor Analysis
20.1 Actavis
20.1.1 Key Facts
20.1.2 Business Description
20.1.3 Business Segmentation
20.1.4 Business Segmentation by Revenue 2012 and 2013
20.1.5 Sales by Geography
20.1.6 Business Strategy
20.1.7 Key Information
20.1.8 SWOT Analysis
20.2 Eli Lilly
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation by Revenue
20.2.4 Sales by Geography
20.2.5 Business Strategy
20.2.6 Key Information
20.2.7 SWOT Analysis
20.3 Pfizer
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Segmentation by Revenue 2014
20.3.4 Business Segmentation by Revenue 2013 and 2014
20.3.5 Geographical Segmentation by Revenue 2014
20.3.6 Business Strategy
20.3.7 Key Developments
20.3.8 SWOT Analysis

21.Other Reports in This Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Epidemiology of Fibromyalgia 2014-2019
Exhibit 3: Pathophysiology of Fibromyalgia
Exhibit 4: Global Fibromyalgia Drugs Market 2014-2019 ($ millions)
Exhibit 5: Global Fibromyalgia Drugs Market: Key Takeaways
Exhibit 6: Fibromyalgia Drugs Market in US 2014-2019 ($ millions)
Exhibit 7: Fibromyalgia Drugs Market in Europe 2014-2019 ($ millions)
Exhibit 8: Global Fibromyalgia Drugs Market by Chemical Class of Drug
Exhibit 9: Global Fibromyalgia Drugs Market by Geography 2014
Exhibit 10: Fibromyalgia: Pipeline Portfolio
Exhibit 11: Major Drivers of Global Fibromyalgia Drugs Market
Exhibit 12: Major Challenges in Global Fibromyalgia Drugs Market
Exhibit 13: Major Trends in Global Fibromyalgia Drugs Market
Exhibit 14: Global Fibromyalgia Drugs Market: Vendor Ranking
Exhibit 15: Pfizer: YoY Global Revenue of Lyrica 2010-2014 ($ millions)
Exhibit 16: Pfizer: Key Takeaways
Exhibit 17: Eli Lilly: YoY Global Revenue of Cymbalta 2010-2014 ($ millions)
Exhibit 18: Eli Lilly: Key Takeaways
Exhibit 19: Actavis: YoY Global Revenue of Savella 2010-2013 ($ millions)
Exhibit 20: Actavis: Key Takeaways
Exhibit 21: Global Fibromyalgia Drugs MarketBusiness Segmentation 2013
Exhibit 22: Global Fibromyalgia Drugs Market Business Segmentation by Revenue 2012 and 2013 ($ millions)
Exhibit 23: Actavis : Sales by Geography ($ millions)
Exhibit 24: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 25: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ millions)
Exhibit 26: Eli Lilly: Sales by Geography 2013
Exhibit 27: Pfizer: Business Segmentation by Revenue 2014
Exhibit 28: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 29: Pfizer: Geographical Segmentation by Revenue 2014



*** 掲載企業 ***

Actavis, Eli Lilly, Pfizer, Daiichi Sankyo, Innovative Med Concepts, Meda, Meiji Seika, Merck Sharp and Dohme, Switch Biotech, Theravance, Tonix, Zynerba Pharmaceuticals

*** レポートのキーワード ***

線維筋痛症治療、医薬品、製薬、パイプライン

*** 調査方法 ***

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(IRTNTR6480 )"線維筋痛症治療薬の世界市場2015-2019" (英文:Global Fibromyalgia Drugs Market 2015-2019)はTechnavio社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。